Market Closed -
Other stock markets
|
Pre-market 07:00:15 am | |||
73.01 USD | +0.83% | 73.12 | +0.14% |
12:34pm | Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program | DJ |
Mar. 22 | Gilead Sciences Completes $4.3 Billion Cymabay Acquisition | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.88% | 90.95B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.77% | 210B | |
+0.96% | 210B | |
-6.69% | 201B | |
-3.51% | 157B |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- News Gilead Sciences, Inc.
- Morgan Stanley Downgrades Gilead Sciences to Equalweight From Overweight, Cuts Price Target to $74 From $84, Citing 'More Balanced Risk/Reward'